Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01221272 · ClinicalTrials.gov registry record · Phase 4
Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging
A Phase 4 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 81
- Enrollment target
NCT01221272 is a Phase 4 study that has completed, run by Gilead Sciences. The registered enrollment target is 81 participants.
The verdict
NCT01221272, a Phase 4 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 81 participants
- Enrollment target
Study Summary
This study enrolled participants with documented exercise-induced myocardial ischemia in order to evaluate whether ranolazine, when taken prior to exercise, can improve blood flow to the heart (myocardial perfusion), as assessed by exercise-induced myocardial perfusion defect size (PDS) and total perfusion deficit (TPD), using gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). This was a 2-period crossover study. The last dose of each period must have been taken 3-4 hours prior to conduct of the exercise SPECT MPI. After the research exercise SPECT MPI was performed at the end of Period 1, participants discontinued the treatment they were randomized to for that period and began the other treatment in Period 2.
Interventions
- BEHAVIORAL Exercise
- DRUG Ranolazine
- DRUG Placebo to match ranolazine
- PROCEDURE SPECT MPI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01221272
The ClinicalTrials.gov registry entry for NCT01221272 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Exercise is the first listed.
NCT01221272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01221272 about?
NCT01221272 is a clinical study titled "Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging". This study enrolled participants with documented exercise-induced myocardial ischemia in order to evaluate whether ranolazine, when taken prior to exercise, can improve blood flow to the heart (myocardial perfusion), as assessed by exercise-induced myocardial perfusion defect size (PDS) and total pe...
What is the current status of trial NCT01221272?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 81 participants. The study started on 2010-09. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01221272?
The interventions under investigation include: Exercise (BEHAVIORAL), Ranolazine (DRUG), Placebo to match ranolazine (DRUG), SPECT MPI (PROCEDURE).
Who is sponsoring clinical trial NCT01221272?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.